Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Tissue Regenix Group's Total Stockholders Equity for the quarter that ended in Jun. 2025 was €25.46 Mil. Tissue Regenix Group's Total Assets for the quarter that ended in Jun. 2025 was €40.91 Mil.
Therefore, Tissue Regenix Group's Equity to Asset Ratio for the quarter that ended in Jun. 2025 was 0.62.
The historical rank and industry rank for Tissue Regenix Group's Equity-to-Asset or its related term are showing as below:
FRA:LSW'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.62 Med: 0.78 Max: 0.98
Current: 0.62
During the past 13 years, the highest Equity to Asset Ratio of Tissue Regenix Group was 0.98. The lowest was 0.62. And the median was 0.78.
FRA:LSW's Equity-to-Asset is not ranked
in the Biotechnology industry.
Industry Median: 0.68
vs FRA:LSW: 0.62
Tissue Regenix Group (FRA:LSW) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Tissue Regenix Group Equity-to-Asset Related Terms
Tissue Regenix Group Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Tissue Regenix Group's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:LSW vs VRTX, REGN, ALNY: Equity-to-Asset Comparison
For the Biotechnology subindustry, Tissue Regenix Group's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tissue Regenix Group Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tissue Regenix Group's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Tissue Regenix Group's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Tissue Regenix Group's Equity to Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tissue Regenix Group (FRA:LSW) has a Equity-to-Asset of 0.62 as of Jun. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Tissue Regenix Group and its competitors. This is 21% below median its historical median of 0.78. Over the past decade, Tissue Regenix Group's Equity-to-Asset has ranged from 0.62 to 0.98.
Is Tissue Regenix Group's Equity-to-Asset too high?
Tissue Regenix Group's current Equity-to-Asset of 0.62 is 21% below median its 10-year median of 0.78. Over the past 10 years, this metric has ranged from a low of 0.62 to a high of 0.98. The Biotechnology industry median Equity-to-Asset is 0.68. Tissue Regenix Group's value of 0.62 is 8.8% below this industry median. Overall, Tissue Regenix Group has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Tissue Regenix Group's Equity-to-Asset compare to VRTX and REGN?
Tissue Regenix Group's Equity-to-Asset of 0.62 can be compared against companies in the Biotechnology industry. The industry median Equity-to-Asset is 0.68. Tissue Regenix Group's value of 0.62 is 8.8% below this benchmark. Historically, Tissue Regenix Group's own Equity-to-Asset has ranged from 0.62 to 0.98 over the past decade. While the company's 10-year median is 0.78 vs. the industry median of 0.68, Tissue Regenix Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tissue Regenix Group's current Equity-to-Asset of 0.62 is 8.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Tissue Regenix Group and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tissue Regenix Group's current Equity-to-Asset is 0.62, which is 21% below median its own 10-year median of 0.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tissue Regenix Group stock overvalued right now?
Tissue Regenix Group (FRA:LSW) has a current Equity-to-Asset of 0.62. The stock's GF Value™ is €0.84, compared to a current price of €0.07 — trading 91.7% below its estimated fair value. The current Equity-to-Asset is 0.62, which is 21% below median its 10-year median of 0.78 and 8.8% below the Biotechnology industry median of 0.68. Tissue Regenix Group's overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Tissue Regenix Group (FRA:LSW), the current Equity-to-Asset is 0.62 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tissue Regenix Group (FRA:LSW) Overvalued in 2026?
Based on GuruFocus' analysis, Tissue Regenix Group stock appears to be undervalued.
The current stock price of €0.07 is trading 91.7% below its estimated GF Value™ of €0.84.
Key valuation signals for FRA:LSW:
Equity-to-Asset: 0.62 (21% below median its 10-year median of 0.78)
GF Value™: €0.84 vs. price of €0.07 (91.7% below fair value)
Industry Position: 8.8% below the Biotechnology median
No single metric tells the full story. See the FRA:LSW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tissue Regenix Group PLC is a pioneering medical technology company engaged in the development of regenerative products. The company incorporates dCELL and BioRinse technology, which helps to address complex and varying clinical needs. Its product portfolio includes Biosurgery, Orthopaedics, and Dental. The company has operations around the world, with special emphasis in the United States.
10GF Score
Get the complete analysis for FRA:LSW
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LSW has been successfully added to your 
